Plasma resistance to activated protein C: An important link between venous thromboembolism and combined oral contraceptives - A short review

European Journal of Contraception and Reproductive Health Care

Volumn 1, Issue 1, 1996, Pages 3-11

  Jespersen, J ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

Author keywords

APC resistance; Cardiovascular disease; Combined oral contraceptives; Factor V Leiden; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROTEIN C;

BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; FEMALE; GENETIC SCREENING; GENETICS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PHYSIOLOGY; POINT MUTATION; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

BLOOD COAGULATION; CONTRACEPTIVES, ORAL, COMBINED; FACTOR V; FEMALE; GENETIC SCREENING; HUMANS; PARTIAL THROMBOPLASTIN TIME; POINT MUTATION; PROTEIN C; RISK FACTORS; THROMBOEMBOLISM;

EID: 0030088870     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189609150650     Document Type: Review

References (57)

1. Bertina RM, Koeleman RPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (London) 1994; 369: 64-7
2. The Consensus Committee. Consensus Development Meeting 1995: combined oral contraceptives and cardiovascular disease. Gynecol Endocrinol 1996; 10: 1-5
3. Jordan MV. Pulmonary embolism. Lancet 1961; 2: 1146-7
4. The Consensus Development Meeting: Metabolic aspects of oral contraceptives of relevance for cardiovascular disease. Am J Obstet Gynecol 1990; 162: 1335-7
5. Carter C, Gent M. The epidemiology of venous thrombosis. In Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Philadelphia: JB Lippincott, 1982: 805-19
6. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' Oral Contraception Study. Br Med J 1989; 298: 165-8
7. Katerdahl DA, Realini JP, Cohen PA. Oral contraceptive use and cardiovascular disease: is the relationship real or due to study bias? J Fam Pract 1992; 35: 147-57
8. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7
9. Thorogood M, Mann J, Murphy M, et al. Risk factors for fatal venous thromboembolism in young women; a case-control study. Int J Epidemiol 1992; 21: 48-52
10. Farmer RT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol 1995; 15: 195-200
11. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82
12. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8
13. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93
14. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593-6
15. Spitzer WO, Lewis MA, Heinemann LA, et al. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-8
16. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Evidence that currently available pills are associated with vascular disease: venous disease. In Hannaford, P.C. and Webb, A.M.C. Evidence-guided Prescribing of the Pill, pp. 61-76. (Carnforth, UK: Parthenon Publishing)
17. Jespersen J. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. Dan Med Bull 1988; 35: 1-33
18. First European Esbjerg Conference on Sex Steroids and Metabolism. Oral contraceptives in the nineties: metabolic aspects - facts and fiction. Am J Obstet Gynecol 1990; 163 (Suppl 2): 273-446
19. Second European Esbjerg Conference on Sex Steroids and Metabolism. Oral contraceptives and cardiovascular disease - from myth to realities. Gynecol Endocrinol 1996; 10 (Suppl. 2)
20. Jespersen J, Gram J. Increased fibrin formation in blood in women above the age of 30 who are both oral contraceptive users and smokers. Fibrinolysis 1996; 10: 9-13
21. Astrup T. The biological significance of fibrinolysis. Lancet 1956; 2: 565-8
22. Astrup T. The haemostatic balance. Thromb Diath Haemorrh 1958; 2: 347-57
23. Kluft C. Disorders of the hemostatic system and the risk of the development of thrombotic and cardiovascular diseases: limitations of laboratory diagnosis. Am J Obstet Gynecol 1990; 163: 305-12
24. Owen J, Kvam D, Nossel HL, et al. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood 1983; 61: 476-82
25. Petersen KR, Sidelmann J, Skouby SO, et al. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol 1993; 168: 32-8
26. Gram J, Munkvad S, Jespersen J. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen. Am J Obstet Gynecol 1990; 163: 438-42
27. Petersen KR, Skouby SO, Sidelmann J, et al. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 1994; 171: 400-5
28. Petersen KR, Skouby SO, Sidelmann J, et al. Assessment of endothelial function during oral contraception in women with insulin-dependent diabetes mellitus. Metabolism 1994; 43: 1379-83
29. a activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76: 826-36
30. Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology. J Clin Pathol 1990; 43: 703-9
31. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-30
32. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3
33. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-8
34. Broekmans AW, Bertina RM, Reinalda-Poot J, et al. Hereditary protein S deficiency and venous thromboembolism. A study in three Dutch families. Thromb Haemost 1985; 53: 273-7
35. Engesser L. Thrombophilia. Disorders of blood coagulation and fibrinolysis. Thesis. Leiden: Krips Repro Meppel, 1988: 1-139
36. Gladson CL, Scharrer I, Hach V, et al. The frequency of type 1 heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22
37. Heijboer H, Brandjes DPM, Büller HR, et al. Deficiencies of coagulation inhibiting and fibrinolytic proteins in out-patients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-16
38. Pabinger I, Brücker S, Kyrle PA, et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinol 1992; 3: 547-53
39. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-7
40. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4
41. de Maat MPM, Jespersen J, Kluft C, et al. Absence of factor V Leiden mutation in Eskimos (Inuit). Lancet 1996; 347: 58-9
42. Rosendaal FR, Bertina RM, Reitsma PH. Evaluation of activated protein C resistance in stored plasma. Lancet 1994; 343: 1289-90
43. Zöller B, Svensson PJ, He X, et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest 1994; 24: 2521-4
44. Trossaërt M, Conard J, Horellou MH, et al. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995; 73: 162-6
45. Sidelmann J, Gram J, Pedersen OD, et al. Influence of plasma platelets on activated protein C resistance assay. Thromb Haemost 1995; 74: 993-4
46. Pedersen OD, Sidelmann J, Gram J, et al. Influence of blood handling on determination of plasma resistance against activated protein C. Fibrinolysis 1996; in press
47. de Ronde H, Bertina R. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6
48. Osterud B, Robertsen R, Asvang GB, et al. Resistance to activated protein is increased in women using oral contraceptives. Blood Coag Fibrinol 1994; 5: 853-4
49. Henkens CMA, Bom VJJ, Seinen AJ, et al. Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4
50. Pedersen OD, Petersen KR, Skouby SO, et al. Oral contraceptives increase plasma resistance against activated protein C in women with insulin-dependent diabetes mellitus. Gynecol Endocrinol 1996; 10: 163-4
51. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and contraceptives. Am J Obstet Gynecol 1995; 173: 210-13
52. Bom van der JG, Kluft C, Bots ML, et al. Factor V mutation, APC resistance and myocardial infarction in the Rotterdam Study. Thromb Haemost 1995; 73: 1814
53. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8
54. Gram J, Jespersen J, Bertina RM. Is the activity of tissue plasminogen activator (t-PA) of clinical relevance in thrombophilia caused by protein S deficiency? Fibrinolysis 1988; 2 (Suppl 2): 51-4
55. Koeleman BPC, Reitsma PH, Allaart CF, et al. APC-resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84: 1031-5
56. Zöller B, Berntsdotter A, Garcia de Frutos P, et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23
57. Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75: 524-5